Cognetivity’s unique cognition-monitoring technology to be deployed to measure positive impact of employee wellness initiatives, enabling direct feedback and program optimization

Vancouver, BC – March 2nd, 2021 – Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) (the “Company” or “Cognetivity”) today announced that it has reached an agreement with Dutch telehealth company Luscii healthtech BV (“Luscii”) regarding the deployment of Cognetivity’s wellness app, OptiMind. Luscii will deploy OptiMind’s sophisticated cognitive measurement capabilities in order to better understand the impact of its innovative human resources policies and corporate wellness initiatives.

Luscii is a provider of remote monitoring services for patients with conditions ranging from cancer and diabetes to Covid-19. It is the Dutch market leader, deployed in over half of hospitals in the Netherlands, and is now active in several other countries, including the UK. This success has been underpinned by innovation, both in its products and services and in its approach to employee welfare. As Luscii rolls out a major new wellness initiative within the business, it will deploy OptiMind to give better personal insights to team members and improve its understanding, via aggregate data, of the overall impact of its investment.

“Luscii supports many thousands of patients and clinicians through remote monitoring.” said Professor Daan Dohmen, Chief Executive of Luscii. “Anything I can do to help improve the working environment for my colleagues will help them and, in turn, help patients and clinicians too,” he said. “Learning what works in this context has been challenging until now, but Cognetivity’s incredible technology opens up new and exciting possibilities for measuring the real impact of targeted programs and I look forward immensely to learning from the insights OptiMind will deliver.”

Employee wellbeing continues to assume growing importance in the business world, with the global corporate wellbeing market forecast to expand from US$53.6 billion in 2018 to US$90.7 billion by 2026. Large employers in the US spent an average of $762 per employee on wellbeing programs in 2019. However, the return on such investments remains unclear, with firms unable to quantify program impact at either an individual or organizational level.

Meanwhile, consumers remain increasingly keen to use technology to track aspects of their physical health, such as activity levels, weight and heart rate – but the prospect of day-to-day measurement of brain performance, particularly in relation to core lifestyle factors such as sleep, exercise and diet, has remained elusive. On top of all this, the pandemic has disrupted working norms. Many people are working from home and therefore unable to access the formal and informal support networks and wellbeing initiatives ordinarily available in the office environment.

OptiMind sits at the confluence of these major global trends. It is a wellness app, created for easy use by consumers, that is nevertheless supported by the same medical-grade cognitive assessment functionality that powers Cognetivity’s flagship clinical product, the ICA. Geared towards the personalized tracking and management of cognitive performance, it is also designed to enable feedback loops between employees and employers for the monitoring of wellbeing and risk. Optimind is also designed with enterprise scale in mind, being capable of serving the needs of millions of concurrent users around the world.

“Many progressive employers have strived to increase the impact of mental wellbeing efforts in the workplace to better support their employees and improve efficiency,” explained Dr Sina Habibi, Cognetivity’s CEO. “Crucially, OptiMind makes it practical and cost-effective to measure the impact of these initiatives. With OptiMind based on the same underlying science and technology that underpins our clinical products, and therefore benefiting from not only clinical validation but also speed and ease of use, our fundamentally different approach to cognitive testing is now opening an entirely new way for companies to support their staff. This is very much the future of working and looking after employees in and out of the workplace, using tools like ours to proactively look after health and improve productivity and safety.”

“The work that Luscii is doing in this area is enormously exciting and we are honoured to be able to contribute to it,” he added. “There has never been a more important time to look after your employees, and there has never been a tool quite like OptiMind to help you to do so.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia. It has achieved regulatory approval for clinical use in the UK and Europe with future clinical approval anticipated in North America and elsewhere in the world.

For more information, please visit: www.cognetivity.com or contact: info@cognetivity.com

For media enquiries, please contact: Josh Stanbury | josh@sjspr.co  | 416-628-7441

Innovate UK EDGE: www.innovateukedge.ukri.org

ON BEHALF OF THE BOARD

“Sina Habibi”

Sina Habibi

Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Cognetivity Neurosciences Ltd.

Cognetivity’s iPad-based Integrated Cognitive Assessment (ICA) well suited to remote use as global demand for telehealth continues to surge

Vancouver, BC – January 12, 2020 – Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) (the “Company” or “Cognetivity”) today announced the expansion of its UK government-funded study on the use of its Integrated Cognitive Assessment (ICA) to identify early-stage cognitive decline in people at risk of developing dementia.

Known as ADePT (Accelerating Dementia Pathway Technologies), the study was launched in January 2020 to investigate the capacity of the ICA to drive major improvements in dementia care pathways in the UK’s National Health Service (NHS) and beyond. Cognetivity is collaborating on the project with Sussex Partnership NHS Trust and the charity Alzheimer’s Research UK, and receiving grant funding from the UK’s innovation agency, Innovate UK, which has invested over £2.5 billion in British businesses since 2007.

So far, participants in the study have been taking ICA tests in person at NHS facilities. However, the project’s expansion, as announced today, will entail the delivery of iPads to participants’ homes and enable them to take the cutting-edge digital assessment remotely, without travelling to hospital and putting themselves at risk of exposure to Covid-19.

Commenting on the announcement, Dr Naji Tabet, consultant old age psychiatrist at Sussex Partnership NHS Trust and the study’s chief investigator, said, “Cognetivity’s ICA provides a much-needed cognitive assessment platform, where patients at home can remotely undertake a more thorough assessment. Currently specialist clinicians are finding virtual assessments challenging, and this challenge is even more acute in primary care due to overwhelming demands on doctors’ time during this pandemic. An effective assessment tool which can inform colleagues’ views about referrals to Memory Assessment Clinics without the need for face to face consultation is very timely”.

The expansion brings the project in line with wider Covid-related developments in the world of healthcare. Since the study commenced early last year, there has been an immense global surge in the popularity of telemedicine: doctors and patients alike have come to appreciate the value of remote consultations, and the global telehealth market is now projected to grow to more than 900% of its 2019 value by 2027.

The ICA offers numerous advantages over traditional pen-and-paper examinations, including its short duration and high classification accuracy, coupled with the absence of a practice effect or any cultural or educational bias. Nevertheless, it is the computerised nature of the ICA and its ease of use, eliminating the need for the presence of a healthcare professional, that positions it particularly well to enable the switch from in-person to unsupervised, remote assessment as the era of telemedicine dawns.

Dr Tabet’s positivity about the expansion of the study was echoed by Dr Chris Kalafatis, Cognetivity’s Chief Medical Officer, who added: “Tragic though the effects of the pandemic have been, Covid has given the world a wake-up call as to the enormous benefits telemedicine can bring. There’s no doubt that the ICA, as a digital tool, can save lives by all too importantly limiting the spread of the virus. But it can also improve quality of life by enabling vast improvements in the efficiency of dementia pathways and the detection of early-stage cognitive decline. The ADePT study, especially in its expanded form, offers us the unique opportunity to enable the ICA to do both.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia. It has achieved regulatory approval for clinical use in the UK and Europe with future clinical approval anticipated in North America and elsewhere in the world.

For more information, please visit: www.cognetivity.com

ON BEHALF OF THE BOARD

“Sina Habibi”

Sina Habibi

Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information: Email: info@cognetivity.com; For media enquiries contact: Josh Stanbury, Email: josh@sjspr.co.uk

SOURCE Cognetivity Neurosciences Ltd.

• Cognetivity one of only seven health tech innovators selected to advance to full accelerator program
• Cohorts receive increased resources and network support to accelerate US market penetration

Vancouver, BC – December 23, 2020 – Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) (the “Company” or “Cognetivity”) today announced that it has been selected by the prestigious Texas Medical Center Innovation Accelerator (TMCx) as one of seven members of the TMCx program. The TMCx is dedicated to identifying breakthrough healthcare technologies and enabling their subsequent commercialization.

The selection is the culmination of a rigorous multi-round selection process. 170 applicants from 20 different countries originally applied, with 21 making it through to the Bootcamp phase and just seven standout healthcare innovators invited to join the full accelerator programme. Cognetivity is the only non-US-based company to join this select cohort.

As a part of the exclusive cohort, Cognetivity will gain access to significant medical networks across the US which are actively looking to advance innovation in order to confront the greatest challenges in healthcare today.

Initial selection phases were based on factors including technological novelty and strength, addressable market size, and overall fit for the TMCx program and partners. The Bootcamp phase allowed Cognetivity to begin exploring commercial opportunities and potential partnerships with TMC’s member institutions and the level of interest and positive feedback received from those institutions was a key factor in the companies chosen to advance.

Notable cohorts from the 2019 fall program included medical imaging platform Arterys which in May, 2020 announced its seventh USFDA approval and $23M in financing bringing its total raised to over $71M.

“Having such immediate access to an engaged network of potential US commercial partners enables companies like ours, with unique technology able to help address a major health crisis, to break through the noise and make meaningful progress quickly.” said Sina Habibi, Cogentivity founder and CEO. “We have been incredibly impressed with the quality of the TMCx program throughout and already have some very exciting partnership opportunities evolving rapidly with some of the TMC members. We look forward to strengthening those relationships and developing further opportunities in the months ahead that build on our early traction in clinical use in the UK NHS.”

Potential savings that could be made through the early and accurate diagnosis of Alzheimer’s have been estimated by the Alzheimer’s Association at up to $7.9 trillion in the US alone. Cognetivity’s novel approach to cognitive testing enables healthcare providers to deliver a highly-sensitive and non-invasive test which can detect the very earliest signs of cognitive impairment. The five minute, iPad or smartphone-administered test, can be taken by patients remotely and requires no medical training or specialist supervision.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia. It has achieved regulatory approval for clinical use in the UK and Europe with future clinical approval anticipated in North America and elsewhere in the world.

For more information, please visit: www.cognetivity.com

ON BEHALF OF THE BOARD

“Sina Habibi”

Sina Habibi

Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information: Email: info@cognetivity.com; For media enquiries contact: Josh Stanbury, Email: josh@sjspr.co.uk

SOURCE: Cognetivity Neurosciences Ltd

Research will utilise Cognetivity’s Integrated Cognitive Assessment (ICA) technology to study potential early-stage cognitive decline in individuals at risk of developing dementia

Vancouver, BC  – Decemeber 1, 2020  – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (FWB: 1UB) (OTCQB: CGNSF) today announced that it will be collaborating with researchers at Oxford University to investigate the use of its Integrated Cognitive Assessment (ICA) in monitoring the cognition of individuals at risk of developing dementia. Participants in the study will take the ICA remotely via their smartphones, offering further insight into the potential of Cognetivity’s digital tool to enhance early-stage dementia diagnosis.

The collaborative project has arisen through the organisations’ shared membership of the prestigious Dementias Platform UK (DPUK) network. A public-private partnership, DPUK counts several of the UK’s highest-ranked universities, medical technology companies and some of the world’s largest pharmaceutical companies among its members, and has received £53 million in funding from the Medical Research Council (MRC) since its launch in 2014. DPUK aims to accelerate research into the origins of dementia by forging relationships between academia and industry, providing a single, shared data repository, and enhancing recruitment in clinical studies via its extensive Great Minds Register of volunteers, from which participants in the Cognetivity-Oxford study will be recruited.

Although dementia is the leading cause of death in England and Wales , its development remains poorly understood and, with traditional cognitive testing methods, patients rarely manage to obtain a diagnosis early enough to receive the maximal benefits of treatment. The study aims to break new ground, using remote, smartphone-based assessment with a view to measuring cognitive decline associated with the earliest stages of disease. In this study, researchers intend to recruit cognitively healthy participants aged 50 and up who may be at risk of cognitive impairment or who are subjectively concerned about their cognition.

The study will be led by Dr. Ivan Koychev, a Senior Clinical Researcher and Specialist Consultant Neuropsychiatrist at Oxford University and the National Health Service, who expressed his enthusiasm for the project. “Dementia is one of the biggest healthcare challenges facing our generation. We now know that the process leading to it starts 15-20 years before symptoms. The healthcare system is not geared up to identify the individuals in its preclinical stages and that is why we are looking to digital technology as a scalable means to point to dementia risk.” Dr. Koychev said. He further states, “Cognetivity’s ICA has great potential to contribute to this. With its unique approach to cognitive testing, it could pave the way for accurate, early-stage dementia diagnosis that, through remote assessment, is in line with what is required for the future of clinical practice and increases accessibility, particularly among populations under-represented in research studies and also Covid-19 affected populations.”

“It’s not hard to see how this kind of testing could revolutionize patient care,” agreed Dr. Sina Habibi , CEO of Cognetivity. “If a tool such as the ICA were available to the millions of people who are at risk, or belong to the so-called “the worried well”, to be able to regularly and accurately check up on their cognition, there would be many more healthy individuals feeling reassured and many more people with dementia accessing treatment as early as possible – a fantastic result. At the same time, the healthcare system would benefit from the cost savings associated with a reduction in unnecessary, in-person cognitive assessments. As ever, the prospect of empowering clinical excellence is what is motivating us as we join forces with Oxford and DPUK in carrying out this research.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia. It has achieved regulatory approval for clinical use in the UK and Europe with future clinical approval anticipated in North America and elsewhere in the world.

For more information, please visit: www.cognetivity.com

ON BEHALF OF THE BOARD
“Sina Habibi”

Sina Habibi
Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Cognetivity Neurosciences Ltd